PEG-rhG-CSF reduced the incidence of neutropenia and improved treatment compliance
neutropenia
EVENTS, NEUTROPENIA
A total of 151 chemotherapy cycles, including 79 cycles in the PEG-rhG-CSF arm and 72 cycles in the rhG-CSF arm, were used to evaluate safety and efficacy. The incidence of grade 1–4 neutropenia in the PEG-rhG-CSF and rhG-CSF groups was 24.05% and 56.94%, respectively. The incidence of grade 3–4 neutropenia was significantly lower in the PEG-rhG-CSF group than in the rhG-CSF group [0 (0%) vs. 4 (5.56%) cycles; Incidence of neutropenia and related events in the two arms * indicates statistically significant difference (The lowest value of ANC throughout treatment was 2.73± 1.02 and 1.91 ± 0.79 × 10